ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z

Abstract Number: 1187

Obesity Burden and Effects of Apremilast on Changes in Cardiometabolic Parameters by Obesity Status in Patients with Psoriasis (PsO) or Psoriatic Arthritis (PsA) in a Real-World Setting
Abstract Number: 0153

Obesity Is Associated with Higher Odds of Malignancy Development Among Dermatomyositis Patients
Abstract Number: 2234

Obesity, Adipokines, and Chronic and Persistent Pain in Rheumatoid Arthritis
Abstract Number: 0950

Obstetric Outcomes in Women with Rheumatic Disease and COVID-19 in the Context of Vaccination Status: Data from the COVID-19 Global Rheumatology Alliance Registry
Abstract Number: 0677

Obstructive Sleep Apnea in Primary Antiphospholipid Syndrome Impacts Damage Accrual
Abstract Number: 0601

Occupational Inhaled Agents Constitute Major Risk Factors for Rheumatoid Arthritis, Particularly in the Context of Genetic Predisposition and Smoking
Abstract Number: 0673

Occurrence and Severity of Bleeding in Adults with Immunogenic Thrombocytopenic Purpura with or Without Antiphospholipid Autoantibodies
Abstract Number: 0314

Olokizumab Improved Patient Reported Outcomes in TNF Incomplete Responder (TNF-IR) Rheumatoid Arthritis Patients: Results from the Phase III Randomized Controlled Trial
Abstract Number: 0313

Olokizumab Improves Patient Reported Outcomes in Moderate to Severely Active Rheumatoid Arthritis Patients Inadequately Controlled by Methotrexate (MTX-IR): Results from the Phase III Randomized Controlled Trial
Abstract Number: 0230

Online Educational Module on Axial Spondyloarthritis Improves the Knowledge and Confidence of Non-rheumatology Providers
Abstract Number: 0215

Online Teaching of Hand Examination Using Student-recorded Videos and Remotely Delivered Feedback: A Pilot Study
Abstract Number: 0435

Onset of ANCA-associated Vasculitides in Systemic Sclerosis: Phenotype, Management and Outcomes
Abstract Number: 0073

Opioid and Pain Medication Prescribing by Rheumatologists for Medicare Part D Beneficiaries from 2013 to 2019
Abstract Number: 0402

Opioid Use and Healthcare Utilization in Adults with PsA and AS
Abstract Number: 0865

Opioid Use in Youth with Inflammatory Bowel Disease (IBD)-related Arthritis
Abstract Number: 0822

Optimal Use of Colchicine in COVID-19 Management from Rheumatologists’ Perspective: A Monocentric Observational Study During the SARS-CoV-2 Delta Variant Pandemic
Abstract Number: 0726

Optimizing Laboratory Medication Safety Monitoring in Patients with JIA to Advance Value-based Care
Abstract Number: 0006

Oral Administration of a Novel Pyrrolopyrimidine Derivative That Inhibits BAFF Signaling Suppresses B Cell Differentiation and Production of Autoantibody in Autoimmune Model Mice
Abstract Number: 1689

Oral Ginger Supplementation Counteracts NETosis in Autoimmune Mouse Models and in Healthy Humans
Abstract Number: 0325

Ordering Practices and Diagnostic Utility of Cardiac MRI in SLE Patients at a Single Academic Institution
Abstract Number: 1891

Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab: A Randomized Placebo-Controlled Trial
Abstract Number: 1661

Osteoclastogenesis and Vascular Endothelial Growth Factor Blood Levels in Patients with Systemic Sclerosis with and Without Calcinosis Cutis
Abstract Number: 0574

Osteoporosis in Elderly Men; An Underestimated and Underdiagnosed Morbid Entity
Abstract Number: 0437

Outcome Measures in Patients with Neurologic Involvement in ANCA-associated Vasculitis: Data from Multicenter Longitudinal Observational Study
Abstract Number: 1872

Outcome of Idiopathic Inflammatory Myositis Patients Who Received Rituximab: A Single Centre Retrospective Study
Abstract Number: 2022

Outcome of Pregnancy in Women with Primary Sjögren’s Syndrome Compared to the General Population: The French Multicenter Prospective GR2 Study
Abstract Number: 0854

Outcome of Uveitis in Juvenile Idiopathic Arthritis and Spondyloarthritis Patients – a 5-year Follow up Study
Abstract Number: 1566

Outcome of Vascular Involvement of Behçet Syndrome Treated with Infliximab: A Retrospective Cohort Study
Abstract Number: 1929

Outcomes and Safety of Anakinra for the Treatment of Multisystem Inflammatory Syndrome in Children
Abstract Number: 1420

Outcomes in Patients with Rheumatoid Arthritis Initiating Monotherapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors
Abstract Number: 0679

Outcomes of Antiphospholipid Antibody Syndrome and Acute Coronary Syndrome: Analysis of National Inpatient Sample 
Abstract Number: 2101

Outcomes of Autoimmune Hemolytic Anemia in Patients with Systemic Lupus Erythematosus: A Nationwide Inpatient Sample Study
Abstract Number: 0866

Outcomes of Children with Uveitis Associated with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV) Treated with Methotrexate and Infliximab
Abstract Number: 1588

Outcomes of Etanercept and Janus Kinase Inhibitor Treatment After First-line Use of Adalimumab in Patients with Rheumatoid Arthritis
Abstract Number: 1082

Outcomes of Methotrexate as an Initial Induction and Maintenance Regimen for Localized Granulomatosis with Polyangiitis: A Retrospective Review
Abstract Number: 0850

Outcomes of Patients with Juvenile Idiopathic Arthritis Following Failure of Initial Tumor Necrosis Factor Inhibitor Medication in the Childhood Arthritis and Rheumatology Research Alliance Registry
Abstract Number: 1976

Outcomes of the First Episode of STEMI in Rheumatoid Arthritis from the National Inpatient Sample Database 2016-2019
Abstract Number: 2057

Outpatient Visit Adherence and Impact on Disease-related Morbidity in Childhood-onset Systemic Lupus Erythematosus (cSLE)
Abstract Number: 1591

Overall and Post-vaccination Prevalence of Severe COVID-19-related Events Among Commercially Insured Patients with Systemic Lupus Erythematosus and the General U.S. Population

Jump to: View All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.